Wellcome Sanger Institute Selects Arima Genomics as HiC Technology Partner; Company Announces Early Access Program for high-coverage HiC
Arima Genomics, Inc., a biotechnology company accelerating the adoption of the genome structure information, announced today that its new high-coverage HiC technology has been evaluated and implemented at the Wellcome Sanger Institute for projects, including the Darwin Tree of Life project, in an effort to explore the true genetic diversity between species and between individuals within a species.
The Wellcome Sanger Institute is one of the world's leading genome science research hubs that advances the world’s understanding of the genetics of human health and disease. The Institute's research programs range from cancer genomics, single-cell human genetics, population human genetics and species evolution, and its findings have unlocked critical insights in the areas of drug development, new treatment options and novel biomaterials.
HiC data captures the three-dimensional folding patterns of genomes within cells, and consequently, it facilitates the assembly of its linear unfolded state. Such a linearized genome is the foundational representation of an organism’s DNA and is commonly used to compare genomes within and between species in order to elucidate the link between genetics and disease. The Wellcome Sanger Institute is using the next generation of Arima Genomics’ HiC kits developed to generate sequencing data with improved coverage uniformity. “The high-coverage HiC data provides more evenly distributed shotgun reads and associated long range linkages that aid the scaffolding of contigs to improve assembly contiguity,” said Michael Quail, Principal Scientific Manager, DNA Pipelines R&D at the Wellcome Sanger Institute. “The newer Arima kits are being used because we found them to be robust across a range of tissue types from diverse vertebrate and invertebrate species. Kit robustness to a diversity of samples is an essential requirement for the Darwin Tree of Life Project.”
Feedback and data generated by early customers helped to optimize toward low-input capability and varied sample storage conditions. “The high-coverage HiC kits generated high signal-to-noise libraries in samples with limited input amounts such as 2uL of zebra finch blood,” said Olivier Fedrigo, Director of the Vertebrate Genome Laboratory, The Rockefeller University. “Additionally, to mimic real world sample collection and storage conditions, we collected blood in ethanol tubes and preserved them at room temperature for a week – the Arima kits generated high-quality data despite potential sample degradation expected from such harsh conditions. Adaptability to field conditions is a key feature for the Vertebrate Genome Project (VGP), the Darwin Tree of Life Project, and the larger Earth BioGenome Project (EBP).”
In response to the community’s expectation that the production scale of genome assembly projects will get bigger, Arima is collaborating with academic partners to validate automation compatibility and optimize workflow speed to ensure quality, efficiency and convenience for the customer. “Nearly 20 years after the first draft assembly of the human genome was released, we are finally in a position to generate genome assemblies affordably at a cost less than $5,000 per gigabase genome size, nearly a million-fold down from $1 billion per gigabase two decades ago,” said Harris Lewin, Distinguished Professor at UC Davis and chair of the EBP. “Thanks to technological advances from industry partners, it is now possible to ascertain assemblies at very fine resolution in part because of the improved read coverage uniformity, and, also quickly in a span of days – creating an inflection point toward launching EBP with the aim to assemble DNA of all the planet’s eukaryote biodiversity, 1.5 million known species, over a period of 10 years.”
In addition to informing the linear unfolded states of genomes, HiC can also inform misfolded states of cancer genomes. In particular, cancer is a disease largely caused by genomic aberrations and such aberrations can be more accurately identified when the genome is observed from its innate three-dimensional structural state as captured by HiC. “Indeed, the folding information from HiC has proven to be an important component in our development of new algorithms for assembling structurally accurate cancer genomes,” said Shilpa Garg, K99 Fellow at Dana Farber Cancer Institute and Harvard Medical School. “More broadly, structurally accurate cancer genomes can help deconvolute the clonal architecture and evolution of tumor aberrations that impact therapeutics.”
As part of the plan to bring the latest Arima high-coverage kits to market, Arima Genomics today announced an Early Access Program. “Through this program, we aim to partner with the community to further validate the utility of genome structure information toward multiple areas of genomic science, from cancer evolution, T2T genome finishing, pan-genome analyses and species evolution, across a broad range of sample types and input amounts,” said Anthony Schmitt, Senior Vice President of Science at Arima Genomics. “We believe that the structural information of the genome is as fundamental as the sequence to shape the next generation of genomic discoveries – via launching relatable products, expanding structural applications, and financing our programs reliably from the proceeds of our Series A from earlier this year, we are excited to be part of this future.”
About Arima Genomics
Arima Genomics, Inc. is a biotechnology company that aims to accelerate the understanding of genome sequence and structure and their role in health, disease, and species evolution. For additional information, please visit: http://www.arimagenomics.com.
CEO, Arima Genomics
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Data from the APOLLO Study Show Clinically Meaningful Response with DARZALEX ® ▼ (daratumumab) Subcutaneous Formulation Regimen After First or Subsequent Relapse in Multiple Myeloma4.12.2020 20:52:00 CET | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson announced results of the Phase 3 APOLLO study showing that the addition of DARZALEX®▼ (daratumumab) subcutaneous (SC) formulation to pomalidomide and dexamethasone (D-Pd) significantly reduced the risk of progression or death by 37 percent, compared to Pd alone in patients with multiple myeloma (MM) after the first or subsequent relapse of disease.1 The APOLLO results, which will be presented on Sunday, December 6 at 9:00 p.m. CET during the American Society of Hematology (ASH) 2020 Annual Meeting and featured in the ASH press briefing (Abstract #112), add to the body of evidence supporting treatment with daratumumab SC-based regimens for patients with relapsed MM. These data were the basis for recent regulatory submissions in Europe and the United States (U.S.) seeking approval for daratumumab SC in combination with Pd for the treatment of patients with relapsed or refractory MM, with two or more prior lines of therapy, includi
Citi Private Bank Issues Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World4.12.2020 17:36:00 CET | Press release
Citi Private Bank has released its Outlook 2021: The New Economic Cycle: Investing for a Post-COVID World. The twice-yearly publication provides in-depth insights into the global economy and financial markets for the coming year and highlights multi-year “unstoppable trends” for client portfolios. This edition outlines why this is a remarkable time to be an investor. Just as the pandemic changed the price of every security when it arrived, the departure of COVID will mark the beginning of a new economic cycle, creating new opportunities for investors. Citi Private Bank expects 2021 will benefit from an economy that demonstrated resilience in the face of the worst global healthcare crisis in more than a century. 2020 was an opportunity for the world to “test drive the future” and make way for growth as the pandemic ebbs. The tailwinds for 2021 are underappreciated: our financial system is strong, government actions to protect individuals and businesses have been effective, technological
Takashi Nagao Appointed President and Chief Executive Officer of Medicago4.12.2020 17:00:00 CET | Press release
Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, today announced Takashi Nagao as the company’s new President and Chief Executive Officer. Prior to becoming President and CEO, Mr. Nagao served as the Chairman of the Board of Medicago, where for the last four years, he has guided Medicago executives to get the company to where it is today. Medicago, a research and development company for the last 20 years, is embarking on a transformative year, one that will see the company build on its R&D roots to become a company that also produces and commercializes vaccines and other immunotherapies. Mr. Nagao has extensive experience leading pharmaceutical companies through the pre-commercial and commercial process and is well positioned to ensure the successful launch of Medicago’s COVID-19 and influenza vaccines, subject to regulatory approvals. Mr. Nagao will continue Medicago’s evolution towards its goal of being a fully operational commercial entity, able to respond
WorldRemit Leads the Way Offering a USD Payout Option in Nigeria4.12.2020 16:46:00 CET | Press release
WorldRemit, a leading digital cross-border payments business has announced that its customers in Nigeria can now receive remittances in foreign currency (USD) through its cash pick up providers. Following the announcement of the Central Bank of Nigeria (CBN) a day before, WorldRemit quickly adapted to the new requirements making it the first digital service to offer its customers worldwide the option of cash pickup in USD in Nigeria. WorldRemit enables Nigerians in over 50 countries around the world to support their family and friends in Nigeria. The decision by the Central Bank of Nigeria (CBN) to allow international money transfers to be paid in foreign currency, is aimed at providing increased liquidity in the foreign exchange market. The bank explained that the new regulation is part of its efforts to liberalize, simplify and improve the receipt and administration of diaspora remittances into Nigeria. Gbenga Okejimi, Country Manager, Nigeria and Ghana, at WorldRemit, said:“ We are
PPC Upgraded to ‘B’ with ‘Stable’ Outlook by S&P4.12.2020 15:16:00 CET | Press release
In its annual research update released on 27 November 2020, S&P upgraded PPC’s stand-alone credit profile (SACP) upward by two notches to ‘B’ from ‘CCC+’, resulting in an overall upgrade of the long-term credit rating of PPC to ‘B’ from ‘B-‘. According to S&P the two notch upgrade in PPC’s standalone corporate rating confirms that the Company’s strategic repositioning and the improved Greek energy market fundamentals have transformed its competitive position, reducing past concerns over its liquidity and long-term sustainability. The ‘Stable’ outlook underscores S&P’s expectation that PPC will continue to deliver on its transformation plan, with solid liquidity and improved margins. PPC’s strategic plan to convert its generation mix toward lower carbon dioxide (CO2) emissions improve its fleet competitiveness and long-term prospects. As mentioned in their report, S&P expects a substantial increase in EBITDA and improvement in credit metrics on the back of higher profitability as PPC ac
Chengdu Launches Online Exhibition of History and Culture to Enhance Cultural Ties With European Countries4.12.2020 13:17:00 CET | Press release
The launching ceremony of Chengdu History and Culture Overseas Virtual Exhibition was held by the Chengdu Chronicles Compilation Committee at Chengdu Chronicles Office on 24 November. The event, along with the unveiling ceremony of Chengdu Chronicles Culture Overseas (Europe) Exchange Cooperation, were witnessed by distinguished guests in many European countries including the Netherlands, Germany and Belgium through video and online connections. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201204005278/en/ On November 24, Gao Zhigang (center), Director of Chengdu Chronicles Compilation Committee at Chengdu Chronicles Office, and other guests attend the launching ceremony of Chengdu History and Culture Overseas Virtual Exhibition. (Photo: Business Wire) Chengdu History and Culture Overseas Virtual Exhibition will also be launched at major foreign media platforms for audiences all over the world. Gao ZhiGang, Director of Che
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint4.12.2020 12:00:00 CET | Press release
Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced top-line results from the Phase 3 clinical trial evaluating the efficacy and safety of the investigational drug TAK-620 (maribavir), in the treatment of transplant recipients with refractory/resistant cytomegalovirus (CMV) infection. The TAK-620-303 (SOLSTICE) trial (NCT02931539) is a multicenter, randomized, open-label, active-controlled trial comparing eight weeks of treatment with either maribavir or investigator assigned treatment (IAT) in transplant recipients with CMV infection refractory or resistant to existing antiviral treatments (i.e., one or a combination of ganciclovir, valganciclovir, foscarnet or cidofovir). The SOLSTICE trial met its primary endpoint, defined as the proportion of patients who achieved confirmed CMV viremia clearance compared to IAT at the end of Study week 8. In addition, the SOLSTICE trial met its key secondary endpoint, defined as achievement of CMV viremia clearance